213 results
6-K
EX-99.1
BLU
Bellus Health Inc
16 Jun 23
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
4:21pm
Court approval and other conditions of closing necessary to complete the Arrangement or for other reasons; (b) risks related to tax matters; (c … , including changes in economic conditions, interest rates, tax legislation or drug regulatory requirements; (g) the potential of a third party making
6-K
EX-99.1
BLU
Bellus Health Inc
2 Jun 23
Notice of Annual and Special Meeting of Shareholders
4:25pm
; and (ii) certain United States tax law matters applicable to optionees who are United States citizens, permanent residents or for whom a benefit under … thereunder (which United States tax law matters do not modify the Plan in respect of any other category of optionee).
In 2023, the Board determined
6-K
EX-99.1
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
TAX CONSIDERATIONS
Holders Resident in Canada
Holders Not Resident in Canada
CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS
Passive Foreign … Investment Company Status
U.S. Federal Income Tax Consequences of the Arrangement to U.S. Holders
INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS
6-K
EX-99.3
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
, but not limited to, the Income Tax Act (Canada) and the United States Internal Revenue Code of 1986, as amended). Any such amounts will be deducted, withheld … . Holder” for United States federal income tax purposes as defined in Instruction #11 below. If you are a U.S. Holder or acting on behalf of a U.S
6-K
EX-99.1
BLU
Bellus Health Inc
16 May 23
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
5:04pm
the Arrangement or for other reasons; (b) risks related to tax matters; (c) the possibility of adverse reactions or changes in business or drug regulatory … and funding risks generally and relating specifically to the Arrangement, including changes in economic conditions, interest rates, tax legislation
6-K
EX-99.1
e9zu18eh9204e51c3
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
6-K
EX-99.2
49pc9627hj
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
6-K
EX-99.1
sov6xj23jo qv5
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
6-K
EX-99.2
19w31ytv70ev9w
27 Apr 23
Material Change Report
6:04am
6-K
EX-99.2
rhy8lkbzof
30 Mar 23
Notice of Annual and Special Meeting of Shareholders
11:22am
6-K
EX-99.1
ol6 9abu7xschtv
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.1
19tooqq2wp9
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
6-K
EX-99.2
0m02bwa
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
tc2l igsic24qb
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
s29htfn atxx
14 Nov 22
Open Market Sale Agreementsm
5:19pm
6-K
EX-99.1
eeiomzr 0j43gzsmehkz
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
F-10
n2eaogaw9owq dvwz942
26 Aug 22
Registration of securities (Canada)
4:48pm
6-K
EX-99.1
750sm5qa
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.2
vaqowq89y 3y
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.1
cbioddrvdl8exvdqa
10 Aug 22
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
4:31pm